Clinical Trial Update: A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults [Phase 3]

View source ↗

Summary

Clinical trial update indicating a Phase 3 study of baricitinib (LY3009104) to delay progression to Stage 3 Type 1 diabetes in at-risk children and adults, curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Baricitinib (baricitinib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Diabetes Mellitus, Type 1 | Phase 3 | Status: RECRUITING